Organised in collaboration with the Hong Kong Chamber of Commerce in Sweden and the Hong Kong Biotechnology Organization (HKBIO), the delegation provides a practical and high-value entry point into Hong Kong and the GBA.
Opportunities for Nordic Biotech and MedTech Companies
- Clinical trials: Hong Kong offers internationally recognised trial sites and an efficient regulatory environment, enabling studies with Asian populations and access to GBA hospital networks.
- Investor access: Venture capital firms, private equity funds, and family offices in Hong Kong are actively investing in biotech, medtech, and digital health innovations, particularly in oncology, immunotherapy, and precision medicine.
- Partnerships: Proximity to leading hospitals and research centres across the GBA opens doors to collaborations in translational medicine, clinical validation, patient recruitment, and technology transfer.
- Market access: For CE-marked medical devices, Hong Kong provides a streamlined registration process and direct access to 15 public hospitals offering free or subsidised care.
- Talent & expertise: Access to a skilled, globally experienced workforce in clinical research, bioinformatics, regulatory affairs, and product development.
Participation fee (SEK 50,000 per person) includes:
- Return flights, accommodation, and meals
- Curated programme with pre-arranged investor 1:1s
- Site visits and executive roundtables with healthcare, innovation, and regulatory stakeholders
- Networking events with local partners
Reach out to delegation lead,
Lucy Robertshaw to learn more
00(46) 070 628 0230
E-mail: lucyrobertshaw@live.co.uk
